Evidence map›Paper›PMID 19822132›Full record

ArticleBrain research2010

The role of nucleus accumbens adenosine-opioid interaction in mediating palatable food intake.

Carolyn E Pritchett, Alicia L Pardee, Sophia R McGuirk, Matthew J Will

Abstract read
In one paragraph

Article in Brain research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Effects of butorphanol on feeding and neuropeptide Y in the rat.Pharmacology, biochemistry, and behavior · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Carolyn E PritchettDepartment of Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, PA 17033, USA.
Alicia L Pardee
Sophia R McGuirk
Matthew J Will
University of Missouri · USPennsylvania State University · US

Funding

Central opioids-cannabinoid interactions and food rewardR03DA024829 · NIDA · UNIVERSITY OF MISSOURI-COLUMBIA · PI WILL, MATTHEW J · 2008 to 2009
$140k
NIDA NIH HHS R03 DA024829
6 · The paper itself

Abstract

Nucleus accumbens micro-opioid stimulation leads to robust increases in the intake of highly palatable foods, such as a high-fat diet. While interactions between opioids and certain striatal neurotransmitters underlying this phenomenon have been explored, many potential interactions have not. Striatal adenosine has been shown to have a significant influence on striatal neurotransmission and locomotor activity behavior, however the interaction between opioids and adenosine on feeding behaviors has received less attention. The present study explored this interaction within the context of opioid-driven consumption of a high-fat diet. Specifically, intra-accumbens administration of selective A1 and A2(A) adenosine receptor ligands, with or without concurrent administration of the micro-opioid agonist (D)-Ala(2),N,Me-Phe(4),Gly-ol(5)-enkaphalin (DAMGO), on high-fat consumption and associated locomotor activity was examined. The A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine (CCPA) had no effect on either baseline or DAMGO-induced locomotor or consumption behaviors associated with the high-fat diet. However, the A2(A) receptor agonist 2-p-(2 carboxyethyl)-phenethylamino-5'-N-ethylcarboxamido adenosine hydrochloride (CGS 21680) and the prodrug of the A2(A) receptor antagonist MSX-2, 3-(3-hydroxypropyl)-8-(m-methoxystyryl)-7-methyl-1-propargylxanthine phosphate disodium salt (MSX-3) produced the expected decrease and increase in locomotor activity, respectively. CGS 21680 had no effect on baseline or DAMGO-driven consumption of the high-fat diet. MSX-3 had no effect on DAMGO-induced locomotor activity but increased DAMGO-induced consumption. Lastly, the increased activity and consumption produced by MSX-3 alone was blocked by prior administration of the opioid antagonist naltrexone. In summary, these results suggest a potential role of striatal adenosine A2(A) receptors in mediating baseline and striatal opioid-mediated intake of a high-fat diet.

Indexed as

Dietary FatsAdenosineAdenosine A1 Receptor AgonistsAdenosine A2 Receptor AgonistsAdenosine A2 Receptor AntagonistsAnimalsCatheterizationCentral Nervous System AgentsEatingEnkephalin, Ala(2)-MePhe(4)-Gly(5)-LocomotionMaleNaltrexoneNarcotic AntagonistsNucleus AccumbensPhenethylamines2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine2-chloro-N(6)cyclopentyladenosineAdenosineAdenosine A1 Receptor AgonistsAdenosine A2 Receptor AgonistsAdenosine A2 Receptor AntagonistsCentral Nervous System AgentsDietary FatsEnkephalin, Ala(2)-MePhe(4)-Gly(5)-MSX 3 compoundNaltrexoneNarcotic AntagonistsPhenethylaminesReceptor, Adenosine A1Receptor, Adenosine A2AReceptors, Opioid, muXanthines

Identifiers

PMID19822132
PMCPMC4443807
OpenAlexW2042092528

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.